



Wednesday, 21 May 2025

Central Daylight Time (CDT)

8:30 AM	Welcome Coffee
	Opening of the Workshop
9:00 AM	Opening Words Charles Flexner, MD Johns Hopkins University School of Medicine, United States Welcome to New Orleans Fred A. Lopez, MD Louisiana State University Health Sciences Center, United States
	Session 1: Advancing Long-Acting Anti-Infectives: Regulatory Insights and Clinical Impact <i>Co-Chairs: Daniel Kuritzkes & Mark Marzinke</i>
9:10 AM	Long-Acting Anti-Infectives: Where Do We Stand? Charles Flexner, MD Johns Hopkins University School of Medicine, United States
9:30 AM	Pharmacological Considerations for Routes of Administration of LAAI Injectable Products Simone Perazzolo, PHD, MSC University of Washington, United States
9:50 AM	Regulatory Considerations for Long-Acting Anti-Infectives: Challenges and Opportunities - VIRTUAL Kellie Schoolar Reynolds, PharmD Center for Drug Evaluation and Research, FDA, United States
10:10 AM	Discussion / Q&A
10:45 AM	Coffee Break
	Session 2: Long-Acting Options for HIV Prevention <i>Co-Chairs: François Venter & Meredith Clement</i>
11:10 AM	Current and Future Perspectives in HIV Prevention: Approved Drugs and Therapies in Development Richard Elion, MD Washington Health Institute, United States
11:30 AM	Long-Acting Antiretroviral Monoclonal Antibodies: Revolutionizing HIV Prevention Huub Gelderblom, MD, MSc, PhD, MPH HVTN (HIV Vaccine Trials Network) / Fred Hutchinson Cancer Center, United States
11:50 AM	Getting It Right This Time: The Impact of PEPFAR Stop Work Orders on Injectable PrEP and Implications for LEN Rollout Stacey Hannah, MHS AVAC, United States
	Oral Abstract Presentation:
12:05 PM	#1 - Proof-of-Concept Study of Oral VH4004280, a New HIV-1 Capsid Inhibitor Paul Benn ViiV Healthcare, United Kingdom
12:15 PM	Discussion / Q&A
12:35 PM	Lunch
1:30 PM	Industry-Supported Symposium by ViiV Healthcare

Session 3: Long-Acting Treatment Options for HIV

Co-Chairs: Rodney Ho & Natella Rakhmanina

- 2:45 PM **Implementation Challenges in LMICs**
Noela Clara Owarwo, MD
Prevention, Care, and Treatment Programme at the Infectious Diseases Institute, Makerere University, Uganda
- 3:05 PM **Laboratory Considerations in the Age of Long-Acting Agents: A Focus on HIV Resistance**
Mark Marzinke, PhD, DABCC, FADLM
Johns Hopkins University School of Medicine, United States

Oral Abstract Presentations:

- 3:25 PM **LB-#1 - What Do Early Adopters of Long-Acting Injectable Cabotegravir-Rilpivirine Think About It?**
Katerina Christopoulos
University of California San Francisco, United States
- 3:35 PM **#2 - Utilization and Effectiveness of Cabotegravir + Rilpivirine in People with HIV (PWH) with Viremia at Treatment Initiation**
Richard Elion
Washington Health Institute, United States
- 3:45 PM **#3 - Novel Ultra-Long-Acting Injectable Formulations of Bictegravir**
Xiaohong Qi
Bostal, LLC, United States

3:55 PM **Discussion / Q&A**

4:15 PM **Coffee Break & Poster Viewing**

Session 4: Navigating Long-Acting Anti-Infective Therapies: Clinical Evidence and Practical Application in Key Populations

Co-Chairs: Richard Elion & Kimberly Scarsi

- 4:45 PM **Pharmacokinetic Considerations of Long-Acting Anti-Infective Administration During Pregnancy**
Robert R. Bies, Pharm.D., Ph.D., FISoP
School of Pharmacy and Pharmaceutical Sciences University at Buffalo, United States
- 5:05 PM **The Long-Acting Anti-Infective Agents for Children and Adolescents: Are We Nearly There Yet?**
Natella Rakhmanina, MD, PhD, FAAP, FCP, AAHIVS
Children's National Hospital, United States

Oral Abstract Presentations:

- 5:25 PM **#4 - Facilitators and Barriers to Long-Acting Injectable Antiretroviral Therapy Uptake among Youth Living with HIV in Cape Town, South Africa: A COM-B Analysis**
Sheree Schwartz
Johns Hopkins University, United States
- 5:35 PM **#5 - Cabotegravir and Rilpivirine in Pregnancy: A Multi-Center Study Evaluating HIV Viral Suppression, Perinatal and Neonatal Outcomes**
William Short
University of Pennsylvania, United States
- 5:45 PM **LB-#2 - Twice-Yearly Lenacapavir PrEP in Cisgender Gay Men, Transgender Women and Men, and Gender-Diverse People (PURPOSE 2)**
Meredith E. Clement
Louisiana State University Health Sciences Center, United States

5:55 PM **Discussion / Q&A**

6:10 PM **End of Day 1**

7:30 PM **Networking Dinner**



Thursday, 22 May 2025

Central Daylight Time (CDT)

Opening Day 2

- 9:00 AM **Opening Words Day 2**
[Daniel Kuritzkes, MD](#)
 Brigham and Women's Hospital / Harvard Medical School, United States

Session 5: Long-Acting Solutions in Tuberculosis Care

Chair: [Daniel Kuritzkes](#)

- 9:10 AM **Clinical Development of Long-Acting Formulations for Treatment and Prevention of Tuberculosis**
[Kimberly Scarsi, PharmD, MS, FCCP](#)
 University of Nebraska Medical Center (UNMC), United States
- 9:30 AM **Translational Framework for LAI Development in Tuberculosis**
[Rada Savic, PhD](#)
 University of California San Francisco, United States

Oral Abstract Presentations:

- 9:50 AM **#6 - Development of Long-Acting Telacebec (Q203) for Treatment of M. Tuberculosis, M. Ulcerans and M. Leprae**
[Martina Kovarova](#)
 University Of North Carolina At Chapel Hill, United States
- 10:00 AM **#7 - First in Human Dose Predictions Scaled from Preclinical Pharmacokinetics for LAI Rifabutin**
[Doaa Ahmed Mohamed](#)
 University of Liverpool, United Kingdom
- 10:10 AM **LB-#3 - Clinical Development of Long-Acting Formulations for TB Treatment and Prevention: Insights from the Bedaquiline Long-Acting TMC207TBC1006 Phase 1 Trial**
[Vivian Cox](#)
 Johnson & Johnson Innovative Medicine, United States

10:20 AM Discussion / Q&A

10:45 AM Coffee Break & Poster Viewing

Session 6: Monoclonal Antibodies in the Treatment of Respiratory and Other Infections

Co-Chairs: [Kimberly Scarsi](#) & [Natella Rakhmanina](#)

- 11:20 AM **Monoclonal Antibodies for RSV Prevention**
[Sarah Hak, MD](#)
 Wilhelmina Children's Hospital, University Medical Center Utrecht, The Netherlands
- 11:40 AM **Long-Acting Therapies for Emerging Infections: Insights from COVID-19**
[Daniel Kuritzkes, MD](#)
 Brigham and Women's Hospital / Harvard Medical School, United States

Oral Abstract Presentation:

- 12:00 PM **#8 - VH3810109 (N6LS) Efficacy and Safety in Adults Who Are Virologically Suppressed: The EMBRACE Study**
[Rulan Griesel](#)
 ViiV Healthcare, United Kingdom

12:10 PM Discussion / Q&A

12:40 PM Lunch

Session 7: Long-Acting Anti-Infectives: Today and Tomorrow

Co-Chairs: Charles Flexner & Rada Savic

- 1:40 PM **The LONGEVITY Project: Long-Acting Anti-Infectives for Malaria, Hepatitis C, and Tuberculosis - **VIRTUAL****
[Andrew Owen, BSS, MSC, PhD, FSB](#)
 University of Liverpool, United Kingdom
- 2:00 PM **Long-Acting Antiretrovirals in Resource-Limited Settings**
[François Venter, MD, FCP, PhD](#)
 Ezintsha, University of the Witwatersrand, South Africa
- 2:20 PM **Prodrugs Create Ultra-Long-Acting Slow Effective Release Therapies**
[Benson Edagwa, PhD](#)
 University of Nebraska Medical Center (UNMC), United States

Oral Abstract Presentations:

- 2:40 PM **#9 - LAPaL: Your Free Digital Compass in the Evolving Long-Acting Therapeutics Landscape**
[Lobna Gaayeb](#)
 Medicines Patent Pool, Switzerland
- 2:50 PM **LB-#4 - Global Perspectives of People Living with Hepatitis B on Long-Acting Antivirals: Survey Results**
[Yasmin Ibrahim](#)
 Hepatitis B Foundation, United States

- 3:00 PM **Long-Acting Injectable Formulation of Ivermectin as a New Vector Control Tool to Reduce Malaria Transmission**
[Quiterie de Beauregard, MBA, MPH](#)
 MedinCell, France

- 3:10 PM **Discussion / Q&A**

Closure of the Workshop

- 3:25 PM **Closing Remarks**
[Charles Flexner, MD](#)
 Johns Hopkins University School of Medicine, United States

- 3:35 PM **End of the Program**